... WhatsApp

Starting Apalutamide Early Helps Men With Advanced Prostate Cancer Live Longer

You are here >> Home > Latest Updates > Uro & Gynec > Prostate Cancer > Starting Apalutamide…

Survival outcomes of apalutamide as a starting treatment impact in real-world patients with metastatic hormone sensitive prostate cancer DOI 10.1038s41391-024-00929-6

When prostate cancer spreads, starting the right treatment early can make a big difference. This new study looked at real-world data from nearly 5,000 men with advanced prostate cancer in the U.S. It compared different treatment combinations to see which worked best.

All men received hormone therapy to lower testosterone, which helps slow the cancer. Some also got added drugs like apalutamide (APA), enzalutamide (ENZ), abiraterone (AAP), or chemotherapy.

The best results were seen in men who started with APA and hormone therapy. Within 3 months, more of these men saw big drops in their PSA levels, including:

⦿ 70% had a 50% drop in PSA,
⦿ 49% had a 90% drop,
⦿ 44% reached undetectable PSA levels.

These numbers were better than with other treatments. At 2 years, more men who started with APA were alive and still responding to treatment. The risk of dying was lower for men on APA compared to all other groups.

The study also found that many patients were still being treated with hormone therapy alone, even though combinations like APA offer better results.

If you or a loved one has metastatic hormone-sensitive prostate cancer, talk to your doctor about starting treatment with apalutamide.

Rate this post
Robotic Cancer Surgery

Exclusive Health Tips and Updates

Best robotic cancer surgery in Ahmedabad
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.